Politico October 29, 2025
FORWARD THINKING
Drugmaker Delix Therapeutics wants patients in an upcoming clinical trial to test its psychedelic-adjacent therapy — in the comfort of their own home.
On Tuesday, the company announced results from an early-stage trial of zalsupindole, a compound that promotes neuroplasticity, or the brain’s ability to learn and adapt. Delix, a biotech company focused on brain health therapeutics, developed zalsupindole as a nonhallucinogenic therapy to treat major depression.
Zalsupindole is an analogue of 5-MeO-DMT, a psychedelic drug derived from desert toad secretions.
The company reported a 12-point reduction in symptoms on the Montgomery-Åsberg Depression Rating Scale, which measures the severity of depression. The results lasted for four weeks after the last dose, when the trial ended.
Even so: The...
Today's Sponsors
Today's Sponsor